6 results
Primary objective:Part 1: To determine the safety, tolerability, and RP2D of a daily dosing schedule (induction) of GSK3745417 Part 2: To evaluate clinical efficacy following the daily dosing *induction* period of GSK3745417 in participants with…
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
A relatively new method to determine margin distance is intraoral resection with a small Ultrasound (US)-probe. US is already used to determine tumor-thickness in tongue cancer preoperatively, because of its high predictive value. Four previous…
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
The aim of this research is to decrease the number of involved margins, resulting in less adjuvant therapy and less local recurrences.
In last decades, ultrasound probes have become smaller, which made adequate intraoral ultrasound of oral tumors possible. Therefore, invasion depth is now determined pre-operatively by intraoral ultrasound for staging of oral cancer. Our feasibility…